Search

Your search keyword '"Saenger, Yvonne"' showing total 192 results

Search Constraints

Start Over You searched for: Author "Saenger, Yvonne" Remove constraint Author: "Saenger, Yvonne" Search Limiters Full Text Remove constraint Search Limiters: Full Text
192 results on '"Saenger, Yvonne"'

Search Results

2. Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma

3. Introducing cancer convergence

4. First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

5. Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation

6. Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States

9. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma

10. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

11. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

15. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data

16. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

19. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma

20. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data.

22. Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

23. Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma: Anti-PD1 before pediatric liver transplant

27. Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma.

29. 872 Neoadjuvant chemoradiotherapy enhances T cell infiltration in pancreatic ductal adenocarcinoma but high percentage of regulatory T cells associates with poor survival

30. Abstract B11: Prognostic biomarkers in stage II-III melanoma

31. CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

32. Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer

34. Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma

35. Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway

36. Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death

37. Additional file 2: of Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition

38. Additional file 12: of Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition

39. Additional file 7: of Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden

40. Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma

41. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial

42. Abstract B31: Multiparameter profiling of abscopal effect (AbE) in a pediatric fibrosarcoma with EML4-NTRK3 fusion

44. LGG-35. IDENTIFICATION OF SETD2 MUTATION IN AN AGGRESSIVE PILOCYTIC ASTROCYTOMA PRESENTING AS AN INFLAMMATORY OPTIC NERVE LESION

45. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

46. 2367

48. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

49. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Catalog

Books, media, physical & digital resources